Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania speaks about Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men.Link to Article:https://www.pennmedicine.org/news/news-releases/2021/october/drugs-designed-for-prostate-cancer-show-promise-for-treating-melanoma-in-menAccording to current research, testosterone enhances melanoma proliferation in melanoma cells by activating ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any known treatments but is abundantly expressed in human melanoma. Researchers at the University of Pennsylvania’s Perelman School of Medicine used melanoma models in mice to demonstrate that medications that target androgen receptors (AR) in prostate cancer…
Author: Editor
Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania speaks about Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men.Link to Article:https://www.pennmedicine.org/news/news-releases/2021/october/drugs-designed-for-prostate-cancer-show-promise-for-treating-melanoma-in-menAccording to current research, testosterone enhances melanoma proliferation in melanoma cells by activating ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any known treatments but is abundantly expressed in human melanoma. Researchers at the University of Pennsylvania’s Perelman School of Medicine used melanoma models in mice to demonstrate that medications that target androgen receptors (AR) in prostate cancer…
Dr. Rupal O’Quinn is a cardiologist in Philadelphia who is affiliated with both Penn Presbyterian Medical Center and Pennsylvania Hospital. She graduated from Rutgers Robert Wood Johnson Medical School with her medical degree. In this video Dr. O’Quinn speaks about her research in Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.04.011Abstract-As the scope of cardio-oncology expands dramatically, both in terms of the number of people impacted and the sorts of therapy it involves, diagnosing acute and late cardiotoxicity from cancer therapeutics has become increasingly crucial. Cardiac magnetic resonance (CMR) is a tool…
Dr. Rupal O’Quinn is a cardiologist in Philadelphia who is affiliated with both Penn Presbyterian Medical Center and Pennsylvania Hospital. She graduated from Rutgers Robert Wood Johnson Medical School with her medical degree. In this video Dr. O’Quinn speaks about her research in Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.04.011Abstract-As the scope of cardio-oncology expands dramatically, both in terms of the number of people impacted and the sorts of therapy it involves, diagnosing acute and late cardiotoxicity from cancer therapeutics has become increasingly crucial. Cardiac magnetic resonance (CMR) is a tool…
Dr. Javier Valero-Elizondo works as a Research Associate at the Center for Outcomes Research at the Houston Methodist Research Institute. In this video, Dr. Valero-Elizondo speaks about Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006AbstractBackgroundFinancial toxicity (FT) is a well-known adverse effect of the high costs of cancer treatment. According to recent studies, a considerable proportion of people with atherosclerotic cardiovascular disease (ASCVD) suffer from FT and its effects.ObjectivesThe goal of this study was to compare FT in those who had neither ASCVD nor cancer, as well as those who had ASCVD but…
Dr. Javier Valero-Elizondo works as a Research Associate at the Center for Outcomes Research at the Houston Methodist Research Institute. In this video, Dr. Valero-Elizondo speaks about Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006AbstractBackgroundFinancial toxicity (FT) is a well-known adverse effect of the high costs of cancer treatment. According to recent studies, a considerable proportion of people with atherosclerotic cardiovascular disease (ASCVD) suffer from FT and its effects.ObjectivesThe goal of this study was to compare FT in those who had neither ASCVD nor cancer, as well as those who had ASCVD but…
Carla R. Lamb, MD an interventional pulmonologist at Lahey Hospital & Medical Center speaks about Veracyte Announces New Expanded Data At Chest Underscoring Percepta Nasal Swab Test’s Ability To Improve Early Lung Cancer Assessment. Link to Article:https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-new-expanded-data-chest-underscoring-perceptaVeracyte, Inc. reported today that new expanded clinical validation data back up the company’s noninvasive Percepta Nasal Swab test’s ability to help clinicians better identify lung cancer risk in patients with lung nodules. The data also suggest that the test performs well in the clinic across a wide range of nodule sizes and cancer stages in current and former smokers, as well as individuals…
Carla R. Lamb, MD an interventional pulmonologist at Lahey Hospital and Medical Center speaks about Veracyte Announces New Expanded Data At Chest Underscoring Percepta Nasal Swab Test’s Ability To Improve Early Lung Cancer Assessment. Link to Article:https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-new-expanded-data-chest-underscoring-perceptaVeracyte, Inc. reported today that new expanded clinical validation data back up the company’s noninvasive Percepta Nasal Swab test’s ability to help clinicians better identify lung cancer risk in patients with lung nodules. The data also suggest that the test performs well in the clinic across a wide range of nodule sizes and cancer stages in current and former smokers, as well as individuals…
Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021 Abstract – 525P – Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data-from-phase-i-dose-escalation-of-a-novel-therapeutic-peptide-st101-targeting 525P Abstract:History:CCAAT/enhancer-binding protein (C/EBP), an oncogenic transcription factor, promotes tumor survival and proliferation while blocking differentiation. ST101 is a C/EBP peptide antagonist having anti-tumor action in glioblastoma (GBM), breast cancer (BC), prostate cancer (PC), melanoma, and other cancer models.Methodologies:In patients…
Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021 Abstract – 525P – Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data-from-phase-i-dose-escalation-of-a-novel-therapeutic-peptide-st101-targeting 525P Abstract:History:CCAAT/enhancer-binding protein (C/EBP), an oncogenic transcription factor, promotes tumor survival and proliferation while blocking differentiation. ST101 is a C/EBP peptide antagonist having anti-tumor action in glioblastoma (GBM), breast cancer (BC), prostate cancer (PC), melanoma, and other cancer models.Methodologies:In patients…
Amy Moore, Ph.D., VP, Global Engagement and Patient Partnerships at LUNGevity Foundation speaks about LUNGevity Foundation Launches New Lung Cancer Patient Gateways. Link to LUNGevity:https://www.lungevity.org/Link to Article:https://www.lungevity.org/news/media-releases/lungevity-foundation-launches-new-lung-cancer-patient-gatewaysThe LUNGevity Foundation, the country’s foremost lung cancer nonprofit, has launched a new resource called Lung Cancer Patient Gateways. The KRAS Patient Gateway is the first to go live, and it will make it easier for cancer patients with the KRAS gene mutation to obtain resources and treatment information, as well as connect with other patients and caregivers.The KRAS Patient Gateway is a user-friendly and easily available information site that provides persons with KRAS…
Amy Moore, Ph.D., VP, Global Engagement and Patient Partnerships at LUNGevity Foundation speaks about LUNGevity Foundation Launches New Lung Cancer Patient Gateways. Link to LUNGevity:https://www.lungevity.org/Link to Article:https://www.lungevity.org/news/media-releases/lungevity-foundation-launches-new-lung-cancer-patient-gatewaysThe LUNGevity Foundation, the country’s foremost lung cancer nonprofit, has launched a new resource called Lung Cancer Patient Gateways. The KRAS Patient Gateway is the first to go live, and it will make it easier for cancer patients with the KRAS gene mutation to obtain resources and treatment information, as well as connect with other patients and caregivers.The KRAS Patient Gateway is a user-friendly and easily available information site that provides persons with KRAS…
Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital in Denmark speaks about the FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Recurrent Cervical Cancer.Link to Article:https://www.medscape.com/viewarticle/960819?src=Pembrolizumab (Keytruda, Merck) and conventional chemotherapy — with or without bevacizumab — have been approved by the US Food and Drug Administration (FDA) as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.The first-line approval comes on the heels of the KEYNOTE-826 trial’s phase 3 data, which were reported at the European Society for Medical Oncology (ESMO) Congress 2021 last month.The FDA also announced the regular approval of…
Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital in Denmark speaks about the FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Recurrent Cervical Cancer.Link to Article:https://www.medscape.com/viewarticle/960819?src=Pembrolizumab (Keytruda, Merck) and conventional chemotherapy — with or without bevacizumab — have been approved by the US Food and Drug Administration (FDA) as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.The first-line approval comes on the heels of the KEYNOTE-826 trial’s phase 3 data, which were reported at the European Society for Medical Oncology (ESMO) Congress 2021 last month.The FDA also announced the regular approval of…
Misako Nagasaka, MD, Ph.D. UCI Health speaks about AnHeart and Innovent Announce Interim Data from Phase â…¡ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting.Link to Article:https://www.businesswire.com/news/home/20210927005229/en/AnHeart-and-Innovent-Announce-Interim-Data-from-Phase-%E2%85%A1-Trial-TRUST-of-Taletrectinib-in-ROS1-Positive-NSCLC-at-the-CSCO-2021-Annual-MeetingAnHeart Therapeutics Co., Ltd, a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class precision oncology therapeutics, and Innovent Biologics, Inc., a world-class biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, metabolic, autoimmune, and other major diseases, announced today interim clinical data from a Phase II trial (TRUST) evaluating t (NSCLC). On September 25-29, 2021, the findings will be presented as…
Misako Nagasaka, MD, Ph.D. UCI Health speaks about AnHeart and Innovent Announce Interim Data from Phase â…¡ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting.Link to Article:https://www.businesswire.com/news/home/20210927005229/en/AnHeart-and-Innovent-Announce-Interim-Data-from-Phase-%E2%85%A1-Trial-TRUST-of-Taletrectinib-in-ROS1-Positive-NSCLC-at-the-CSCO-2021-Annual-MeetingAnHeart Therapeutics Co., Ltd, a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class precision oncology therapeutics, and Innovent Biologics, Inc., a world-class biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, metabolic, autoimmune, and other major diseases, announced today interim clinical data from a Phase II trial (TRUST) evaluating t (NSCLC). On September 25-29, 2021, the findings will be presented as…
Dr. Lorenzo Gervaso works in the Division of Gastrointestinal Medical Oncology and Neuroendocrnine Tumors at the European Institute of Oncology in Milan Italy. In this video Dr. Gervaso discusses Venous and Arterial Thromboembolism in Patients With Cancer.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.03.001AbstractIn cancer patients, venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality. Myocardial infarction and stroke are common complications of arterial thromboembolism. Subgroups of people are more at risk, with greater rates of cancers such pancreatic, stomach, and multiple myeloma. Most patients with active cancer who are hospitalized for medical reasons or…
Dr. Lorenzo Gervaso works in the Division of Gastrointestinal Medical Oncology and Neuroendocrnine Tumors at the European Institute of Oncology in Milan Italy. In this video Dr. Gervaso discusses Venous and Arterial Thromboembolism in Patients With Cancer.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.03.001AbstractIn cancer patients, venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality. Myocardial infarction and stroke are common complications of arterial thromboembolism. Subgroups of people are more at risk, with greater rates of cancers such pancreatic, stomach, and multiple myeloma. Most patients with active cancer who are hospitalized for medical reasons or…
Alan Dal Pra, MD from the University of Miami – Sylvester Cancer Center, Clinical Director, Director, Radiation Oncology Clinical Research Program speaks about ASTRO 2021 Abstract – 94 Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP).Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/5dd0f31e-127e-4877-91e4-f2ff0571e5d5- The bodyPurpose/Objective(s):PSA levels before salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) are crucial prognostic and predictive factors after prostate surgery. GC has the ability to independently predict prostate cancer outcomes and may aid in the individualization of treatment. The role of the GC in patients treated in…
Alan Dal Pra, MD from the University of Miami – Sylvester Cancer Center, Clinical Director, Director, Radiation Oncology Clinical Research Program speaks about ASTRO 2021 Abstract – 94 Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP).Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/5dd0f31e-127e-4877-91e4-f2ff0571e5d5- The bodyPurpose/Objective(s):PSA levels before salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) are crucial prognostic and predictive factors after prostate surgery. GC has the ability to independently predict prostate cancer outcomes and may aid in the individualization of treatment. The role of the GC in patients treated in…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about the ATA 2021 Abstract – Long-term Efficacy and Safety of Larotrectinib in Pts with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://virtual.oxfordabstracts.com/#/event/public/2083/submission/169Body of the Abstract:Goal:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor that has a 75 percent objective response rate (ORR) in 206 evaluable adult and pediatric patients with non-primary CNS malignancies (Hong et al, ASCO 2021). In an extended cohort with longer follow-up, we report on the…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about the ATA 2021 Abstract – Long-term Efficacy and Safety of Larotrectinib in Pts with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://virtual.oxfordabstracts.com/#/event/public/2083/submission/169Body of the Abstract:Goal:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor that has a 75 percent objective response rate (ORR) in 206 evaluable adult and pediatric patients with non-primary CNS malignancies (Hong et al, ASCO 2021). In an extended cohort with longer follow-up, we report on the…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about ESMO 2021 – Abstract – 534P – Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status – and – Long-term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/534P.html.pdfBackground:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor approved in over 40 countries and by the European Medicines Agency for the treatment of TRK fusion cancer in adults…
David S. Hong, MD, the deputy chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center speaks about ESMO 2021 – Abstract – 534P – Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status – and – Long-term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-positive Thyroid Carcinoma.Link to Abstract:https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/534P.html.pdfBackground:Larotrectinib is a first-in-class, highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor approved in over 40 countries and by the European Medicines Agency for the treatment of TRK fusion cancer in adults…
Srinivas Gaddam, MD, Interventional Gastroenterologist, Assistant professor of Medicine at Cedars-Sinai Cancer speaks about Study: Incidence of Pancreatic Cancer Rising in Younger Women.Link to Article:https://www.cedars-sinai.org/newsroom/study-incidence-of-pancreatic-cancer-rising-in-younger-women/Link to Jama Abstract:https://jamanetwork.com/journals/jama/fullarticle/2785590?resultClick=1 Researchers at Cedars-Sinai Cancer Center discovered that the incidence of pancreatic cancer, which has historically been higher in males than in women, has grown in both men and women over the last decade, with a considerably higher proportional increase among younger women.According to the findings, the average annual percentage change in total pancreatic cancer cases grew by 0.78 percent in women and 0.90 percent in males, with no statistically significant difference between…
Srinivas Gaddam, MD, Interventional Gastroenterologist, Assistant professor of Medicine at Cedars-Sinai Cancer speaks about Study: Incidence of Pancreatic Cancer Rising in Younger Women.Link to Article:https://www.cedars-sinai.org/newsroom/study-incidence-of-pancreatic-cancer-rising-in-younger-women/Link to Jama Abstract:https://jamanetwork.com/journals/jama/fullarticle/2785590?resultClick=1 Researchers at Cedars-Sinai Cancer Center discovered that the incidence of pancreatic cancer, which has historically been higher in males than in women, has grown in both men and women over the last decade, with a considerably higher proportional increase among younger women.According to the findings, the average annual percentage change in total pancreatic cancer cases grew by 0.78 percent in women and 0.90 percent in males, with no statistically significant difference between…
Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline.Link to Article:https://www.panthera-bio.com/news/At the Rutherford Cancer Centre North East, the first multisite oncology trial conducted by the independent sector in the UK has begun treating its first patient. This collaboration between Rutherford Health and Panthera will increase the UK’s capacity to conduct oncology research and give cancer patients more treatment alternatives. More than ten other oncology trials are currently in the works for the…
Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline.Link to Article:https://www.panthera-bio.com/news/At the Rutherford Cancer Centre North East, the first multisite oncology trial conducted by the independent sector in the UK has begun treating its first patient. This collaboration between Rutherford Health and Panthera will increase the UK ‘s capacity to conduct oncology research and give cancer patients more treatment alternatives. More than ten other oncology trials are currently in the works for…
Hossein Taghizadeh, MD-PhD from the Medical University of Vienna; University Hospital of St. Poelten speaks about MAP 2021 Abstract – 20P – Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors.Link to Abstract:https://cslide.ctimeetingtech.com/map2021_virtual/attendee/confcal_1/presentationBackground:Based on the particular molecular profiles of extensively pretreated cancer patients following failure of all traditional treatments, we investigated the efficacy, feasibility, and limitations of using mTOR inhibitors.Methods:We looked at the genetic characteristics of 70 cancer patients in this single-center, real-world retrospective analysis of our precision medicine platform. Next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry were used to examine tumor…
Hossein Taghizadeh, MD-PhD from the Medical University of Vienna; University Hospital of St. Poelten speaks about MAP 2021 Abstract – 20P – Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors.Link to Abstract:https://cslide.ctimeetingtech.com/map2021_virtual/attendee/confcal_1/presentationBackground:Based on the particular molecular profiles of extensively pretreated cancer patients following failure of all traditional treatments, we investigated the efficacy, feasibility, and limitations of using mTOR inhibitors.Methods:We looked at the genetic characteristics of 70 cancer patients in this single-center, real-world retrospective analysis of our precision medicine platform. Next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry were used to examine tumor…
Dr. Farhat Latif Khanim, Ph.D., and Professor Chris Bunce, BSc, Ph.D., along with Professor Mark Drayson MBChB Ph.D. FRCPath from the University of Birmingham speak about Triple-drug combo could prove key weapon in fight against cancer.  This is only been researched in MDS.  Link to Article: https://www.birmingham.ac.uk/news/latest/2021/10/triple-drug-combo-in-fight-against-cancer.aspx  MDS affects around 7,000 people in the UK, and many patients die as a result of the disease progressing to acute myeloid leukaemia (AML), a more severe blood cancer. AML has a terrible prognosis in general, but it’s even worse when it’s caused by MDS.  AML kills patients swiftly…
Dr. Farhat Latif Khanim, Ph.D., and Professor Chris Bunce, BSc, Ph.D., along with Professor Mark Drayson MBChB Ph.D. FRCPath from the University of Birmingham speak about Triple-drug combo could prove key weapon in fight against cancer.  This is only been researched in MDS.  Link to Article: https://www.birmingham.ac.uk/news/latest/2021/10/triple-drug-combo-in-fight-against-cancer.aspx  MDS affects around 7,000 people in the UK, and many patients die as a result of the disease progressing to acute myeloid leukaemia (AML), a more severe blood cancer. AML has a terrible prognosis in general, but it’s even worse when it’s caused by MDS.  AML kills patients swiftly…
Andrew J. Brenner MD, Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECTâ„¢ clinical trial speaks about Rhenium-186 NanoLiposome (186RNL) from its ReSPECTâ„¢ clinical trial in recurrent glioblastoma (GBM).Link to Study:https://s24.q4cdn.com/705376798/files/doc_presentations/2021/08/Brenner_LMD-13_ReSPECT-LM-Maximum-tolderated-dose-safety-and-efficacy-of-intraventricular-Rhenium-186-Nanoliposome-(186RNL)-for.pdfDesign of the Study:• A multi-center, open-label, dose-escalation study assessing the safety, tolerability, and distribution of 186RNL through intrathecal infusion to the ventricle in patients with LM after routine surgical, radiation, and/or chemotherapy treatment.• With a starting dose of 6.6 mCi in a volume of 5 mL, a modified Fibonacci dose escalation was used,…
Andrew J. Brenner MD, Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECTâ„¢ clinical trial speaks about Rhenium-186 NanoLiposome (186RNL) from its ReSPECTâ„¢ clinical trial in recurrent glioblastoma (GBM).Link to Study:https://s24.q4cdn.com/705376798/files/doc_presentations/2021/08/Brenner_LMD-13_ReSPECT-LM-Maximum-tolderated-dose-safety-and-efficacy-of-intraventricular-Rhenium-186-Nanoliposome-(186RNL)-for.pdfDesign of the Study:• A multi-center, open-label, dose-escalation study assessing the safety, tolerability, and distribution of 186RNL through intrathecal infusion to the ventricle in patients with LM after routine surgical, radiation, and/or chemotherapy treatment.• With a starting dose of 6.6 mCi in a volume of 5 mL, a modified Fibonacci dose escalation was used,…
Aaron L. Schwartz, MD, Ph.D., Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania speaks about Measuring the Scope of Prior Authorization Policies – Applying Private Insurer Rules to Medicare Part B.Link to Abstract:https://jamanetwork.com/journals/jama-health-forum/fullarticle/2780396Points to Remember -Question: How common are medical services that require prior authorization and how much do they cost?Findings:This cross-sectional study looked at medical services paid for by government-administered Medicare Part B, which doesn’t require prior authorization, for about 6.5 million beneficiaries. The study found that 2.2 services per beneficiary per year would have required prior authorization under the coverage…
Aaron L. Schwartz, MD, Ph.D., Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania speaks about Measuring the Scope of Prior Authorization Policies – Applying Private Insurer Rules to Medicare Part B.Link to Abstract:https://jamanetwork.com/journals/jama-health-forum/fullarticle/2780396Points to Remember -Question: How common are medical services that require prior authorization and how much do they cost?Findings:This cross-sectional study looked at medical services paid for by government-administered Medicare Part B, which doesn’t require prior authorization, for about 6.5 million beneficiaries. The study found that 2.2 services per beneficiary per year would have required prior authorization under the coverage…
Amar U. Kishan, MD, Associate Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center speaks about the ASTRO 2021 Abstract Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/3a92a692-4d67-4c3e-8090-17b848cb1ee5Body:Purpose/Objective(s):To analyze the impact of androgen deprivation therapy (ADT) use and duration with definitive radiotherapy (RT) in localized prostate cancer in the first global individual patient data (IPD) meta-analysis of randomized trials.Materials/Methods:International trial groups (NRG/RTOG,…
Amar U. Kishan, MD, Associate Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center speaks about the ASTRO 2021 Abstract Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/3a92a692-4d67-4c3e-8090-17b848cb1ee5Body:Purpose/Objective(s):To analyze the impact of androgen deprivation therapy (ADT) use and duration with definitive radiotherapy (RT) in localized prostate cancer in the first global individual patient data (IPD) meta-analysis of randomized trials.Materials/Methods:International trial groups (NRG/RTOG,…
Erin Murphy, MD Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic speaks about ASTRO 2021 Abstract – 3258 Neurocognitive Function Following Concurrent Radiotherapy and Temozolomide for Adult Patients With Low-Grade Glioma.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/27f970a0-a161-48c6-adc4-064924c2d044Case:Goal:RTOG 0424 showed that patients with high-risk low-grade glioma (LGG) who received concurrent temozolomide (TMZ) and radiation (RT) followed by adjuvant temozolomide (RT+TMZ) had a longer life than historical controls. The long-term effects of this therapy method on neurocognitive results are unknown. We wanted to see how neurocognitive parameters changed in adult LGG patients before and after RT+TMZ.Components:We looked at 22 LGG patients who had been treated…
Erin Murphy, MD Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic speaks about ASTRO 2021 Abstract – 3258 Neurocognitive Function Following Concurrent Radiotherapy and Temozolomide for Adult Patients With Low-Grade Glioma.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/27f970a0-a161-48c6-adc4-064924c2d044Case:Goal:RTOG 0424 showed that patients with high-risk low-grade glioma (LGG) who received concurrent temozolomide (TMZ) and radiation (RT) followed by adjuvant temozolomide (RT+TMZ) had a longer life than historical controls. The long-term effects of this therapy method on neurocognitive results are unknown. We wanted to see how neurocognitive parameters changed in adult LGG patients before and after RT+TMZ.Components:We looked at 22 LGG patients who had been treated…
Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine at Penn Medicine speaks about the Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.Link to Article:https://www.sciencedirect.com/science/article/pii/S0302283821020595Summary -Origins:The discovery of germline mutations in DNA repair genes has major implications for the personalized treatment of prostate cancer patients (PrCa).Mission:Determine the genetic testing burden and identify DNA repair genes associated with localized PrCa in a diverse academic biobank.Participants, setting, and design:A cross-sectional study of 2391 PrCa patients with localized PrCa was conducted.Measurement of outcomes and statistical analysis:In 1588 localized PrCa patients and 3273 cancer-free males, genetic ancestry and mutation rates…
Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine at Penn Medicine speaks about the Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.Link to Article:https://www.sciencedirect.com/science/article/pii/S0302283821020595Summary -Origins:The discovery of germline mutations in DNA repair genes has major implications for the personalized treatment of prostate cancer patients (PrCa).Mission:Determine the genetic testing burden and identify DNA repair genes associated with localized PrCa in a diverse academic biobank.Participants, setting, and design:A cross-sectional study of 2391 PrCa patients with localized PrCa was conducted.Measurement of outcomes and statistical analysis:In 1588 localized PrCa patients and 3273 cancer-free males, genetic ancestry and mutation rates…
John C. Breneman, MD, principal investigator, and Medical Director of the Cincinnati Children’s/UC Health Proton Therapy Center, UC Health radiation oncologist, and professor emeritus at the University of Cincinnati College of Medicine The trial is supported by Emily Daugherty, M.D., assistant professor of radiation oncology at UC and a UC Health radiation oncologist, and Anthony Mascia, Ph.D., DABR, adjunct assistant professor of radiation oncology at UC and Director of Medical Physics at the Cincinnati Children’s/UC Health Proton Therapy Center and John Perentesis, MD, Directory of Pediatric Oncology, Cincinnati Children’s Hospital. Speaks about Varian and the Cincinnati Children’s/UC Health Proton Therapy…
John C. Breneman, MD, principal investigator, and Medical Director of the Cincinnati Children’s/UC Health Proton Therapy Center, UC Health radiation oncologist, and professor emeritus at the University of Cincinnati College of Medicine The trial is supported by Emily Daugherty, M.D., assistant professor of radiation oncology at UC and a UC Health radiation oncologist, and Anthony Mascia, Ph.D., DABR, adjunct assistant professor of radiation oncology at UC and Director of Medical Physics at the Cincinnati Children’s/UC Health Proton Therapy Center and John Perentesis, MD, Directory of Pediatric Oncology, Cincinnati Children’s Hospital. Speaks about Varian and the Cincinnati Children’s/UC Health Proton Therapy…
Karen Winkfield, MD, Ph.D. is the executive director of the Meharry-Vanderbilt Alliance, professor of Radiation Oncology and Ingram Professor of Cancer Research at Vanderbilt University Medical Center, and professor of Medicine at Meharry Medical College speaks about President Biden appoints Karen Winkfield to National Cancer Advisory Board. Link to Article:https://www.newswise.com/articles/president-biden-appoints-karen-winkfield-to-national-cancer-advisory-boardKaren Winkfield, MD, Ph.D., has been named by President Joe Biden to the National Cancer Advisory Board, where she will serve a six-year term and help steer federal cancer activities.The board advises the Secretary of the United States Department of Health and Human Services and the Director of the National Cancer…
Karen Winkfield, MD, Ph.D. is the executive director of the Meharry-Vanderbilt Alliance, professor of Radiation Oncology and Ingram Professor of Cancer Research at Vanderbilt University Medical Center, and professor of Medicine at Meharry Medical College speaks about President Biden appoints Karen Winkfield to National Cancer Advisory Board. Link to Article:https://www.newswise.com/articles/president-biden-appoints-karen-winkfield-to-national-cancer-advisory-boardKaren Winkfield, MD, Ph.D., has been named by President Joe Biden to the National Cancer Advisory Board, where she will serve a six-year term and help steer federal cancer activities.The board advises the Secretary of the United States Department of Health and Human Services and the Director of the National Cancer…
Chirag Shah, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 66 Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/b6437add-873a-4710-b4bd-0153a3d5cb8bIntention:There is an unmet need to identify women with DCIS who have a low recurrence risk and could avoid radiotherapy (RT) after breast-conserving surgery (BCS), as well as those who have a high recurrence risk after BCS plus RT.Components:At sites in Sweden, the United States, and Australia, pathology, clinical data, and FFPE tissue samples were evaluated for 485 women treated for DCIS with…
Chirag Shah, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 66 Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features.Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/b6437add-873a-4710-b4bd-0153a3d5cb8bIntention:There is an unmet need to identify women with DCIS who have a low recurrence risk and could avoid radiotherapy (RT) after breast-conserving surgery (BCS), as well as those who have a high recurrence risk after BCS plus RT.Components:At sites in Sweden, the United States, and Australia, pathology, clinical data, and FFPE tissue samples were evaluated for 485 women treated for DCIS with…
Paul L. Nguyen, MD, Professor, Radiation Oncology, Harvard Medical School, Vice-Chair for Clinical Research, Genitourinary Disease Cancer Leader for Radiation Oncology, Radiation Oncology, Dana-Farber Cancer Institute, Dana-Farber|Harvard Cancer Center speaks about ASTRO 2021 Abstract – 95 Validation of a 22-Gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/0d611c23-3eee-4918-bdcf-3cadc805a0b7Link to Study:https://clinicaltrials.gov/ct2/show/NCT04513717Objective:Decipher is a prognostic 22-gene genomic classifier (GC) that has been prospectively verified after prostate surgery. In this study, we used three randomized phase III high-risk definitive radiotherapy trials to confirm the GC’s…
Paul L. Nguyen, MD, Professor, Radiation Oncology, Harvard Medical School, Vice-Chair for Clinical Research, Genitourinary Disease Cancer Leader for Radiation Oncology, Radiation Oncology, Dana-Farber Cancer Institute, Dana-Farber|Harvard Cancer Center speaks about ASTRO 2021 Abstract – 95 Validation of a 22-Gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. Link to Abstract:https://plan.core-apps.com/myastroapp2021/abstract/0d611c23-3eee-4918-bdcf-3cadc805a0b7Link to Study:https://clinicaltrials.gov/ct2/show/NCT04513717Objective:Decipher is a prognostic 22-gene genomic classifier (GC) that has been prospectively verified after prostate surgery. In this study, we used three randomized phase III high-risk definitive radiotherapy trials to confirm the GC’s…